Research Article
Clinical Efficacy of Methotrexate Combined with Iguratimod on Patients with Rheumatoid Arthritis and Its Influence on the Expression Levels of HOTAIR in Serum

Jingya Tan,1 Jiaqiang Dan,2 and Yi Liu1
1Department of Rheumatology and Immunology, The People’s Hospital of Wenjiang, Chengdu 611130, China
2Department of Breast and Thyroid Surgery, Chengdu Fifth People’s Hospital, Chengdu 611130, China

Correspondence should be addressed to Yi Liu; kebipa4355@163.com

Received 29 July 2021; Revised 13 October 2021; Accepted 18 October 2021; Published 12 November 2021

Objective. This study was designed to explore the clinical efficacy of methotrexate combined with iguratimod on patients with rheumatoid arthritis (RA) and its influence on the expression levels of HOTAIR in serum.

Methods. A total of 268 RA patients were selected as research objects, 145 patients received methotrexate alone were used as a control group (CG), 123 patients received methotrexate combined with iguratimod were taken as a research group (RG), and serum of 60 healthy people undergoing physical examination was selected as a healthy control group (HCG). The therapeutic value of two therapeutic methods for RA was compared, and the HOTAIR expression in serum was detected by qRT-PCR.

Results. Compared with methotrexate used alone, the joint use of methotrexate and iguratimod could provide better clinical efficacy for RA patients and would not increase the incidence of adverse events. HOTAIR was highly expressed in the serum of RA patients, and its expression decreased after treatment.

Conclusion. Combination therapy of methotrexate and iguratimod is a safe and effective way to treat RA patients, which can be popularized clinically.

1. Introduction

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammatory synovitis and progressive joint destruction [1]. RA is the most common connective tissue disease, with a prevalence rate of 0.5% to 2% in the general population, and the incidence in women is higher than that in men, with a ratio of 3 : 1 [2]. RA itself and treatment can lead to a variety of complications, such as increased risk of cardiovascular diseases, diabetes, and osteoporotic fracture, which have a serious negative impact on life and health of patients [3, 4]. Therefore, it has become a hot research topic to explore treatment methods that can provide effective therapeutic effects and improve prognosis.

Methotrexate has been used to treat RA since the 1980s, and it is still the first-line drug for RA treatment to this day [5]. Therapy based on methotrexate is the core of rheumatoid arthritis. For most patients with rheumatoid arthritis, methotrexate is recommended as the first antirheumatic drug to improve diseases [6], but its long-term use will lead to increased drug resistance. Methotrexate and other anti-rheumatic drugs were recommended in the 2012 guidelines of the American College of Rheumatology (ACR) to treat RA [7]. Iguratimod is an orally active small molecule compound, which is approved in Japan as an antirheumatic drug to improve diseases [8]. In a 52-week multicenter study of more than 2000 RA patients, iguratimod was shown to be safe and effective in treating RA [9]. A clinical study conducted in China found that, compared with methotrexate, iguratimod showed no less efficacy and less side effects [10]. Long noncoding RNA (lncRNA) refers to RNA 200 nucleotides in length and does not participate in protein production [11]. Hox transcript antisense intergenic RNA (HOTAIR), the first lncRNA to be identified, exists on chromosome 12 and has been proved to have a role in the regulation of chromatin state and epigenetic mechanisms within
its different target transcripts. HOTAIR has been found to be expressed differentially in RA. HOTAIR is a 2,158bp lncRNA located at the boundary of HOXC gene cluster, which is involved in the occurrence and development of various diseases [12]. However, little is known about the downstream signaling pathway of lncRNAs in regulating autoimmunity and inflammation. More studies are warranted to elucidate this issue in future. It is also prospective to investigate novel diagnostic and therapeutic strategies for RA by targeting lncRNAs.

Increased inflammatory mediator levels were linked to autoimmune diseases accompanied by chronic or repeated inflammation. Many cytokines, such as interleukin- (IL-) 6 and tumor necrosis factor- (TNF-) α, play a significant role in RA pathogenesis. TNF-α is a protein mainly produced by activated macrophages and monocytes. It participates in human inflammatory response and immune response and is essential to maintain homeostasis [13].

At present, there are few and incomplete researches on the efficacy and safety of methotrexate combined with iguratimod in treating RA. Therefore, this study mainly explored the efficacy and safety of the combination therapy of methotrexate and iguratimod and analyzed its influence on the expression levels of HOTAIR and TNF-α, which is aimed at providing a safe and effective treatment method for RA patients.

2. Materials and Methods

2.1. General Information. A total of 268 RA patients admitted to the People’s Hospital of Wenjiang from July 2017 to January 2019 were selected as the research objects. Among them, 145 patients received methotrexate alone were selected as the control group (CG), and the remaining 123 patients received methotrexate combined with iguratimod were selected as the research group (RG). Inclusion criteria were as follows: patients all conformed to RA-like diagnostic criteria [14], those who signed an informed consent, and patients who received no drugs for rheumatoid arthritis [14], those who signed an informed consent, and patients who received no drugs for rheumatoid arthritis. Exclusion criteria were as follows: patients all conformed to RA-like diagnostic criteria [14], those who signed an informed consent, and patients who received no drugs for rheumatoid arthritis.

2.2. Treatment Methods. Patients in the CG were treated by methotrexate (China Tonghua Maoxiang Pharmaceutical Co., Ltd., SFDA Approval No: H22022674). The method of use is as follows: 10 mg/time, once a week; 12.5 mg/time after two weeks, twice a week; and 15 mg/time after four weeks, once a week until the end of the experiment. And it was taken orally. On the basis of the CG, those in the RG were treated by iguratimod (China Sincere Pharmaceutical Co., Ltd., SFDA Approval No: H20110084), twice a day, 25 mg/dose. Every 12 weeks is one course of treatment, and patients from both groups continue to treat for two courses of treatment.

2.3. Outcome Measures. After the treatment, the efficacy was evaluated: markedly effective: symptoms disappeared completely, physical signs improved by more than 75%, and C-reactive protein (CRP) and erythrocyte sedimentation rate decreased significantly and fell to the normal range; effective: symptoms partially improved, physical signs improved by more than 30%, and CRP and ESR decreased to some extent, but did not fall within the normal range; ineffective: symptoms and signs did not improve, and CRP and ESR did not significantly decrease. Total effective = markedly effective + effective.

The clinical symptoms of the two groups were observed and recorded, including the number of joint swelling, joint tenderness, and morning stiffness time before and after treatment.

DAS28 evaluation standard [15] was used to evaluate the disease activity of patients before and after treatment; >5.1 was high disease activity, <3.2 was low disease activity, and <2.6 was disease remission.

Visual analogue scale (VAS) [16] was used to evaluate the pain degree of patients before and after treatment, with a painless score of 0. The higher the score was, the more severe the pain was.

Barthel index [17] was used to score the self-care ability of patients before and after treatment, including 10 items such as decoration, walking on flat ground, dressing, eating, and bathing, with a total score of 100 points. The higher the score was, the better the self-care ability was.

Adverse events. The incidence of adverse events after treatment between the two groups was compared, mainly including transaminase elevation, leukopenia, renal function and liver function damage, dizziness, diarrhea, nausea and vomiting, hypertension, and infection.

QLQ-C30 [18] was used to evaluate the quality of life of patients six months after treatment, including four items of disease control, life behavior, exercise, and psychological and emotional changes. Each item scored 100 points, and the higher the score was, the better the quality of life was.

The serum of patients in the CG and the RG was collected, respectively, before and after treatment. qRT-PCR and ELISA were used to detect the expression levels of HOTAIR and TNF-α in patients’ serum before and after treatment. The experimental process was strictly carried out in accordance with the kit instructions of TRIzol extraction kit (Wuhan Chundu Biotechnology Co., Ltd., China, CDLG-4396), reverse transcription kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., China, FP209), human TNF-α ELISA kit (Biolake, China, ECA0020), etc.

2.4. Statistical Treatment. SPSS 21.0 (IBM Corp, Armonk, NY, USA) was used for statistical analysis, and GraphPad Prism 7 was used to draw the data picture. The counting data were under chi-square test, comparison of the measurement data between the two groups was under independent samples t test, and paired t test was used for comparison before and after treatment in the group. Comparison of the measurement data from more than two groups was conducted by one-way analysis of variance, correctness of statistical value was verified by post hoc test (Tukey HSD...
3. Results

3.1. Comparison of General Data between Patients in the Two Groups. There was no significant difference between the CG and the RG in general data such as gender, age, weight, education level, dietary preference, place of residence, exercise habits, marital status, history of smoking, and history of drinking (P > 0.05) (Table 1).

3.2. Comparison of Clinical Efficacy between Patients in the Two Groups. The total effective rate of the RG was 86.18%, significantly higher than that of the CG (70.34%), with statistically significant difference (P < 0.05) (Table 2).

3.3. Comparison of Improvement of Clinical Symptom of Patients between the Two Groups before and after Treatment. There was no significant difference in the number of joint swelling, joint tenderness, and morning stiffness time between the CG and the RG before treatment (P > 0.05). After treatment, the three abovementioned symptoms in the two groups significantly improved compared with those before treatment, and the improvement in the RG was more significant than that in the CG (P < 0.05) (Table 3).

3.4. Comparison of VAS, DAS28, and Barthel Scores of Patients between the Two Groups before and after Treatment. There was no significant difference in VAS, DAS28, and Barthel scores of patients between the two groups before treatment (P > 0.05). After treatment, VAS and DAS28 scores of those in both groups decreased significantly, and the decrease in the RG was more significant than that in the CG, while Barthel score was opposite (P < 0.05) (Table 4).

3.5. Comparison of Adverse Events of Patients between the Two Groups. After treatment, adverse events occurred in patients from both groups, but there was no significant difference in the incidence of adverse events such as transaminase elevation, leukopenia, renal and liver function damage, dizziness, diarrhea, nausea, vomiting, hypertension, and infection between both groups (P > 0.05) (Table 5).

3.6. Comparison of QLQ-C30 Score of Patients between the Two Groups. The QLQ-C30 scale in the RG was significantly higher than that in the CG (P < 0.05), as shown in Table 6.

3.7. Comparison of the Expression Levels of Serum HOTAIR and TNF-α in Each Group. Before treatment, the expression levels of HOTAIR and TNF-α in serum of patients in the CG and the RG were significantly higher than those in the HCG (P < 0.05), while there was no significant difference between the CG and the RG (P > 0.05). After treatment, the expression levels of HOTAIR and TNF-α in serum of patients in the two groups decreased significantly, and their expression in the RG was lower than that in the CG (P < 0.05) (Figure 1).

3.8. Correlation Analysis between HOTAIR and TNF-α. The correlation between serum HOTAIR and TNF-α in 268 RA patients before treatment was analyzed by Pearson analysis. The results showed that HOTAIR was positively correlated with TNF-α (r = 0.643, P < 0.001) (Figure 2).

4. Discussion

Methotrexate mainly inhibits the synthesis of thymine and purine by inhibiting dihydrofolate reductase, thus inhibiting the activity of immune cells and achieving the therapeutic purpose [19]. Iguratimod is a new antirheumatic drug with
It can suppress the production of immunoglobulin and various inflammatory cytokines, promote the differentiation of bone cells, inhibit the generation of osteoclasts, and reduce bone absorption and joint destruction [21]. Some research results revealed that the joint use of methotrexate and iguratimod was superior to iguratimod or methotrexate alone. The tables below summarize the results of two studies comparing the efficacy and safety of these treatments.

### Table 2: Comparison of clinical efficacy of patients between the two groups (n(%)).

| Group          | Markedly effective | Effective | Ineffective | Total effective rate |
|----------------|--------------------|-----------|-------------|----------------------|
| Control group  | 44 (30.34)         | 58 (40.00)| 43 (29.66)  | 102 (70.34)          |
| Research group | 70 (56.91)         | 36 (29.27)| 17 (13.82)  | 106 (86.18)          |

χ²: 9.602  P: 0.002

### Table 3: Comparison of improvement of clinical symptoms in patients between the two groups before and after treatment (x ± s).

| Group                     | Time             | Control group (n = 145) | Research group (n = 123) | t   | P     |
|---------------------------|------------------|-------------------------|--------------------------|-----|-------|
| Number of joint swelling  | Before treatment | 15.57 ± 4.25            | 14.81 ± 5.03             | 1.341 | 0.181 |
|                           | After treatment  | 8.56 ± 3.52             | 4.34 ± 2.69              | 10.872 | <0.001 |
| Number of joint tenderness| Before treatment | 8.54 ± 1.35             | 8.23 ± 1.42              | 1.829  | 0.069 |
|                           | After treatment  | 5.45 ± 0.74             | 3.01 ± 0.56              | 29.998 | <0.001 |
| Morning stiffness time    | Before treatment | 3.38 ± 0.66             | 3.31 ± 0.56              | 0.927  | 0.355 |
|                           | After treatment  | 2.67 ± 0.33             | 1.64 ± 0.33              | 18.695 | <0.001 |

Note: Compared with before treatment, *P was less than 0.05.

### Table 4: Comparison of VAS, DAS28, and Barthel scores of patients before and after treatment between the two groups (score, x ± s).

| Group                     | Time             | Control group (n = 145) | Research group (n = 123) | t   | P     |
|---------------------------|------------------|-------------------------|--------------------------|-----|-------|
| VAS score                 | Before treatment | 8.21 ± 1.75             | 8.11 ± 1.87              | 0.452 | 0.652 |
|                           | After treatment  | 5.14 ± 1.42             | 3.19 ± 0.81              | 13.480 | <0.001 |
| DAS28 score               | Before treatment | 6.53 ± 1.45             | 6.34 ± 1.61              | 1.016  | 0.311 |
|                           | After treatment  | 3.77 ± 0.64             | 2.61 ± 0.59              | 15.323 | <0.001 |
| Barthel score             | Before treatment | 64.24 ± 8.24            | 65.56 ± 7.65             | 1.350  | 0.178 |
|                           | After treatment  | 81.34 ± 6.35            | 88.24 ± 5.52             | 9.407  | <0.001 |

Note: Compared with before treatment, *P was less than 0.05.

### Table 5: Comparison of adverse events of patients in the two groups after treatment (n(%)).

| Group                             | Control group (n = 145) | Research group (n = 123) | χ² | P     |
|-----------------------------------|-------------------------|--------------------------|----|-------|
| Transaminase elevation            | 23 (15.86)              | 16 (13.01)               | 0.436 | 0.509 |
| Leukopenia                        | 12 (8.28)               | 14 (11.38)               | 0.733 | 0.392 |
| Renal and liver function damage   | 9 (6.21)                | 11 (8.94)                | 0.722 | 0.396 |
| Dizziness                         | 27 (18.62)              | 24 (19.51)               | 0.034 | 0.853 |
| Diarrhea                          | 19 (13.10)              | 23 (18.70)               | 1.577 | 0.209 |
| Nausea and vomiting               | 23 (15.86)              | 29 (23.58)               | 2.533 | 0.112 |
| Hypertension                      | 7 (4.83)                | 5 (4.07)                 | 0.090 | 0.764 |
| Infection                         | 15 (10.34)              | 10 (8.13)                | 0.386 | 0.534 |

### Table 6: Comparison of QLQ-C30 score of patients between the two groups (score, x ± s).

| Group                     | Control group (n = 145) | Research group (n = 123) | t   | P     |
|---------------------------|-------------------------|--------------------------|-----|-------|
| Disease control           | 80.24 ± 6.25            | 85.24 ± 5.56             | 6.863 | <0.001 |
| Life behavior             | 81.24 ± 5.34            | 89.56 ± 4.87             | 13.231 | <0.001 |
| Exercise                  | 74.21 ± 4.45            | 79.78 ± 4.67             | 9.982  | <0.001 |
| Psychological emotion     | 77.24 ± 7.67            | 86.32 ± 5.33             | 11.057 | <0.001 |
methotrexate monotherapy for RA patients and was also effective for patients with poor response to previous anti-rheumatic drug therapy [22]. Other research results showed that the joint use of methotrexate and iguratimod had better efficacy on active RA than methotrexate alone and did not increase the incidence of adverse events [23]. Our results indicated that the total effective rate of the RG was significantly higher than that of the CG. After treatment, the clinical symptoms, VAS score, DAS28 score, Barthel score, and QLQ-C30 score of the RG were all better than those of the CG, and there was no significant difference in the incidence of adverse events between the two groups. This represented that methotrexate combined with iguratimod was a more effective way to treat RA. The reason we suspected might be that the joint use of the two might jointly inhibit the production of inflammatory factors, thus reducing the inflammatory response. Subsequently, we detected the TNF-α level in serum of both groups and found that its level of the RG was significantly lower than that of the CG after treatment, which indicated that methotrexate combined with iguratimod could jointly inhibit the production of inflammatory factors.

**Figure 1:** Comparison of the expression levels of serum HOTAIR and TNF-α in each group. (a, b) The expression levels of HOTAIR and TNF-α in serum of patients in the CG and the RG were significantly higher than those in the HCG (P < 0.05). (c, d) Compared with before treatment, the expression levels of serum HOTAIR and TNF-α of patients in the two groups decreased significantly after treatment, and their expression in the RG was lower than that in the CG (P < 0.05). Note: Compared with the HCG, *P was less than 0.05. Compared with before treatment, a P in the group was less than 0.05. Compared with the CG, b P was less than 0.05.

**Figure 2:** Correlation analysis between HOTAIR and TNF-α. Pearson analysis showed that there was a significant positive correlation between HOTAIR and TNF-α (r = 0.643, P < 0.001).
at present [24]. HOTAIR is an important member of lncRNAb, which has been discovered. It is involved in the occurrence of many diseases, such as gastric cancer, esophageal squamous cell carcinoma, and nasopharyngeal carcinoma [25–27]. Recently, some researches have found that HOTAIR has certain connection with arthritis diseases, for example, some research results have indicated that HOTAIR is highly expressed in osteoarthritis cartilage [28]. Other research results showed that the HOTAIR expression level is upregulated in blood monocytes and serum exosomes of RA patients but downregulated in differentiated osteoclasts and rheumatoid synovial cells, and its overexpression can reduce the expression of matrix metalloproteinase 2 (MMP-2) and MMP-13 [29]. MMP may play a role in many pathological processes, including inflammation, cardiovascular diseases, pulmonary diseases, and cancer. MMP-9 is implicated in the development of a variety of autoimmune diseases, including systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, RA, and multiple sclerosis [30]. It was detected that downregulated HOTAIR significantly suppressed MMP-9 secretion. Furthermore, in RA patients, the serum level of HOTAIR had a significantly positive correlation with MMP-9 level, erythrocyte sedimentation rate (ESR), hemoglobin (Hb), and platelets count. This agrees partially with the work of Wang and others who found that downregulated HOTAIR leads to suppression of MMP-2 and MMP-9 secretion. They also demonstrated that HOTAIR knockdown in vitro and in vivo significantly decreased the levels of MMP-2 and MMP-9 [31–33].

According to our research results, the HOTAIR expression in serum of patients in the CG and the RG was significantly higher than that in the HCG. After treatment, its expression decreased markedly, and there was a remarkable positive correlation between serum HOTAIR and TNF-α expression decreased markedly, and there was a remarkable positive correlation between serum HOTAIR and TNF-α expression.

5. Conclusion

In conclusion, compared with methotrexate used alone, the joint use of methotrexate and iguratimod can provide better clinical efficacy for RA patients, improve their symptoms and life treatment, and will not increase the occurrence of adverse events. Besides, HOTAIR may participate in the pathogenesis of RA.

Data Availability

The authors confirm that the data supporting the findings of this study are available within the article.

Ethical Approval

Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and/or falsification, double publication and/or submission, and redundancy) have been completely observed by the authors.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jingya Tan and Jiaqiang Dan performed the experiments, analyzed data and wrote the manuscript. Yi Liu designed the study. All the authors agreed to be accountable for the accuracy and integrity of all aspects of the research. Jingya Tan and Jiaqiang Dan contributed equally to this study as co-first authors.

References

[1] P. C. Taylor, E. C. Keystone, D. van der Heijde et al., “Baricitinib versus placebo or adalimumab in rheumatoid arthritis,” The New England Journal of Medicine, vol. 376, no. 7, pp. 652–662, 2017.
[2] Z. X. Yunt and J. J. Solomon, “Lung disease in rheumatoid arthritis,” Rheumatic Diseases Clinics of North America, vol. 41, no. 2, pp. 225–236, 2015.
[3] A. Boonen and J. L. Severens, “The burden of illness of rheumatoid arthritis,” Clinical Rheumatology, vol. 30, no. S1, pp. 3–8, 2011.
[4] L. Hartman, L. A. Rasch, T. Klausch et al., “Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial,” Trials, vol. 19, no. 1, p. 67, 2018.
[5] B. Friedman and B. Cronstein, “Methotrexate mechanism in treatment of rheumatoid arthritis,” Joint, Bone, Spine, vol. 86, no. 3, pp. 301–307, 2019.
[6] G. S. Hazlewood, C. Barnabe, G. Tomlinson, D. Marshall, D. J. Devoe, and C. Bombardier, “Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis,” Cochrane Database of Systematic Reviews, vol. 2016, article CD010227, 2016.
[7] J. A. Singh, D. E. Furst, A. Bharat et al., “2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis,” Arthritis Care & Research, vol. 64, no. 5, pp. 625–639, 2012.

[8] K. Tanaka, T. Yamaguchi, and M. Hara, “Iguratimod for the treatment of rheumatoid arthritis in Japan,” Expert Review of Clinical Immunology, vol. 11, no. 5, pp. 565–573, 2015.

[9] T. Mimori, M. Harigai, T. Atsumi et al., “Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: final report of a 52-week, multicenter postmarketing surveillance study,” Modern Rheumatology, vol. 29, no. 2, pp. 314–323, 2019.

[10] L. Lu, C. Bao, M. Dai et al., “Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate,” Arthritis Care & Research, vol. 61, no. 7, pp. 979–987, 2009.

[11] M. Hajjari and A. Salavaty, “HOTAIR: an oncogenic long noncoding RNA in different cancers,” Cancer Biology & Medicine, vol. 12, p. 1, 2015.

[12] K. Kim, I. Jutooru, G. Chadalapaka et al., “HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer,” Oncogene, vol. 32, no. 13, pp. 1616–1625, 2013.

[13] L. Wang, Q. Chen, C. Shi, H. Lv, X. Xu, and L. Yu, “Changes of serum TNF-α, IL-5 and IgE levels in the patients of mycoplasma pneumonia infection with or without bronchial asthma,” International Journal of Clinical and Experimental Medicine, vol. 8, p. 3901, 2015.

[14] T. Neogi, D. Aletaha, A. J. Silman et al., “The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: phase 2 methodological report,” Arthritis and Rheumatism, vol. 62, no. 9, pp. 2582–2591, 2010.

[15] J. Fransen, M. C. W. Creemers, and P. Van Riel, “Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria,” Rheumatology, vol. 43, no. 10, pp. 1252–1255, 2004.

[16] A. P. Singh, V. Kohli, and S. J. S. Bajwa, “Intravenous analgesia with opioids versus femoral nerve block with 0.2% ropivacaine as preemptive analgesic for fracture femur: a randomized comparative study,” Anesthesia, essays and researches, vol. 10, p. 338, 2016.

[17] K. Takahashi, N. Kamide, M. Suzuki, and M. Fukuda, “Quality of life in people with Parkinson’s disease: the relevance of social relationships and communication,” Journal of Physical Therapy Science, vol. 28, no. 2, pp. 541–546, 2016.

[18] M. C. Lee, H. Park, B. C. Lee, G. H. Lee, and I. J. Choi, “Comparison of quality of life between open and endoscopic thyroidectomy for papillary thyroid cancer,” Head & Neck, vol. 38, no. S1, pp. E827–E831, 2016.

[19] M. Ikeda, K. Watanabe, T. Hirai et al., “Mizoribine synchronized methotrexate therapy should be considered when treating rheumatoid arthritis patients with an inadequate response to various combination therapies,” Internal Medicine, vol. 56, no. 10, pp. 1147–1152, 2017.

[20] X. Li, X. C. Liu, Y. L. Song, R. T. Hong, and H. Shi, “Suspected drug-induced liver injury associated with iguratimod: a case report and review of the literature,” BMC Gastroenterology, vol. 18, no. 1, p. 130, 2018.

[21] H. A. Mucke, “Iguratimod: a new disease-modifying antirheumatic drug,” Drugs Today, vol. 48, no. 9, pp. 577–586, 2012.

[22] Z. Xia, J. Lyu, N. Hou, L. Song, X. Li, and H. Liu, “Iguratimod in combination with methotrexate in active rheumatoid arthritis,” Zeitschrift für Rheumatologie, vol. 75, no. 8, pp. 828–833, 2016.

[23] X. W. Duan, X. L. Zhang, S. Y. Mao, J. J. Shang, and X. D. Shi, “Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial,” Clinical Rheumatology, vol. 34, no. 9, pp. 1513–1519, 2015.

[24] L. Li, B. Liu, O. L. Wapinski et al., “Targeted disruption of Hotair leads to homeotic transformation and gene derepression,” Cell Reports, vol. 5, no. 1, pp. 3–12, 2013.

[25] X. H. Liu, M. Sun, F. Q. Nie et al., “Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer,” Molecular cancer, vol. 13, p. 92, 2014.

[26] X. S. Ge, H. J. Ma, X. H. Zheng et al., “HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway,” Cancer Science, vol. 104, no. 12, pp. 1675–1682, 2013.

[27] Y. Nie, X. Liu, S. Qu, E. Song, H. Zou, and C. Gong, “Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival,” Cancer Science, vol. 104, no. 4, pp. 458–464, 2013.

[28] D. Xing, J. Q. Liang, Y. Li et al., “Identification of long noncoding RNA associated with osteoarthritis in humans,” Orthopaedic Surgery, vol. 6, no. 4, pp. 288–293, 2014.

[29] J. Song, D. Kim, J. Han, Y. Kim, M. Lee, and E. J. Jin, “PBMC and exosome-derived Hotair is a critical regulator and potent marker for rheumatoid arthritis,” Clinical and Experimental Medicine, vol. 15, no. 1, pp. 121–126, 2015.

[30] O. G. Shaker, R. H. Mahmoud, O. O. Abdelaleem et al., “Expression profile of long noncoding RNAs, Inc-Cox2, and HOTAIR in rheumatoid arthritis patients,” Journal of Interferon & Cytokine Research, vol. 39, no. 3, pp. 174–180, 2019.

[31] M. Ram, Y. Sherer, and Y. Shoenfeld, “Matrix metalloproteinase 9 and autoimmune diseases,” Journal of Clinical Immunology, vol. 26, no. 4, pp. 299–307, 2006.

[32] D. L. Scott, F. Wolfe, and T. W. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010.

[33] Y. Wang, Z. Li, S. Zheng et al., “Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers,” Oncotarget, vol. 6, no. 34, pp. 35684–35698, 2015.

[34] L. Magyari, D. Varszegi, E. Kovesdi et al., “Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications,” World Journal of Orthopaedics, vol. 5, no. 4, pp. 516–536, 2014.